22.有關制酸劑使用之敘述，下列何者正確？
(A)制酸劑會與CYP2C9 inhibitor有交互作用
(B)肌酸酐廓清率低於30 mL/min時，含鎂的制酸劑不需調整劑量
(C)制酸劑的作用時間會因為與食物併用而從30分鐘延長至3小時
(D)高劑量的含鈣制酸劑與benzbromarone作用會產生milk-alkali syndrome

(A)制酸劑(ex:~prazole)跟CYP3A4、CYP2C19有關(不是CYP2C9)  (B)肌酸酐廓清率低於30 mL/min時，含鎂的制酸劑需調整劑量

參考資料：

國考用書Applied Therapeutics: The Clinical Use of Drugs 

樓上說的那個

制酸劑=antacid，不是含金屬離子的那些鹽類嗎0.0
-prazole是PPI吧

https://www.uptodate.com/contents/the-milk-alkali-syndrome

Patients who appear to be at higher risk for milk-alkali syndrome include older individuals, those susceptible to volume depletion (including patients on thiazide diuretics), and those on medications that reduce the GFR, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or nonsteroidal antiinflammatory drugs [13]. Patients with chronic kidney disease [4], including patients on dialysis, and pregnant women are also at increased risk. A less common risk factor for milk-alkali syndrome is nicotine-substitute chewing gum, which can provide a significant calcium load when utilized in large quantities